Current Therapeutic Research
Volume 64, Supplement A , Pages A30-A42, 2003

Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate (45 mg/kg per day) for the treatment of uncomplicated acute otitis media

  • Stan L. Block, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Stan L. Block, MD Kentucky Pediatric Research 201 South Fifth Street Bardstown, KY 40004
    • Kentucky Pediatric Research, Bardstown, Kentucky, USA
  • ,
  • Antonio Arrieta, MD

      Affiliations

    • Division of Infectious Disease, Children's Hospital of Orange County, Orange, California, USA
  • ,
  • Matthew Seibei, MD

      Affiliations

    • Arnold Palmer Hospital for Children and Women, Orlando, Florida, USA
  • ,
  • Samuel McLinn, MD

      Affiliations

    • Scottsdale Pediatric Center, Scottsdale, Arizona, USA
  • ,
  • Stephen Eppes, MD

      Affiliations

    • Division of Infectious Diseases, Jefferson Medical College and duPont Hospital for Children, Wilmington, Delaware, USA
  • ,
  • Mary J. Murphy, MD, MPH

      Affiliations

    • Pfizer Inc, New York, New York, USA

Accepted 2 July 2003.

Abstract 

Background: The long half-life of azithromycin allows for single-dose oral therapy for acute otitis media (AOM).

Objective: This study was designed to compare the efficacy and safety of single-dose azithromycin with 10-day, twice-daily amoxicillin/clavulanate for the treatment of new-onset, uncomplicated AOM in children.

Methods: Children aged 6 months to 12 years with new-onset AOM were randomly assigned to receive either a single 30-mg/kg dose of azithromycin or standard-dose amoxicillin/clavulanate (45 mg/kg per day divided BID for 10 days) in a double-blind, double-placebo, multicenter clinical trial. The diagnosis of AOM was based on specific clinical signs and symptoms, and was confirmed by pneumatic otoscopy and acoustic reflectometry (level ≥3). Clinical response was assessed on days 12–16 and 28–32.

Results: Mean (SD) age of children receiving azithromycin (n = 173) or amoxicillin/clavulanate (n = 173) was 2.7 (2.3) years and 3.4 (2.8) years, respectively, with 43% and 36% ≤2 years of age. Clinical success rates (intent-to-treat) for azithromycin and amoxicillin/clavulanate, respectively, were 87% and 88% (95% CI, −9.2 to 6.5) on day 12–16 and 75% and 75% (95% CI, −10.2 to 10.5) on day 28–32. The incidences of treatment-related adverse events for azithromycin and amoxicillin/clavulanate were 16.8% and 22.5%, respectively. Corresponding rates of diarrhea were 6.4% and 12.7%, respectively. Vomiting, which was generally mild, occurred in 7 children in each group. One azithromycin patient and 5 amoxicillin/clavulanate patients discontinued treatment because of adverse events. The compliance rate for azithromycin was significantly higher than that for amoxicillin/clavulanate (99% vs 83%; P < 0.001).

Conclusions: In this trial comparing the efficacy of single-dose azithromycin (30 mg/kg) with amoxicillin/clavulanate (45 mg/kg per day) for the treatment of new-onset, uncomplicated AOM, no differences were detected between the 2 regimens. Single-dose azithromycin was generally well tolerated and provides an alternative to conventional oral regimens for AOM.

Keywords:  acute otitis media, amoxicillin/clavulanate, azithromycin, short-course therapy

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0011-393X(03)80015-2

Current Therapeutic Research
Volume 64, Supplement A , Pages A30-A42, 2003